Dry Herb or Concentrates: Comparing Materials and Devices

What distinguishes the starting materials?

Flower contains a plant matrix. An extract or concentrate has been processed and may contain certain constituents in a different ratio. The processing step alone does not describe the actual composition of the batch.

Flower is also not chemically identical across samples. A strain name or an outward characteristic is no substitute for analysis. The same applies to concentrates, where terms such as wax, shatter, and rosin are equally insufficient. A meaningful comparison therefore begins with the material report.

The cannabis botany section explains the source sample; the extracts overview covers processing and product terminology. Both levels should remain visible in any device comparison.

Which questions need to be resolved before a comparison?

The table organises material and device questions. It is not a ranking. A handling advantage, for example, does not demonstrate an advantage in the chemical composition of the aerosol produced.

A useful article does not assume that one side is always “more natural” or the other always “purer”. Such value judgements require a clear definition and appropriate evidence.

Why is device approval decisive?

The design must be suited to the intended material. A mechanically insertable pad or capsule does not constitute universal permission for arbitrary products. Liquid carriers, viscous materials, and dry particles each impose different requirements.

Check the exact model and the current instructions. A statement about an earlier device may be unsuitable for a successor model. Third-party accessories must also be distinguished from an express manufacturer approval.

In particular, a cannabis oil intended for oral use is not automatically a suitable inhalation material. Product name, carrier substances, and intended route of administration must all correspond. The current manufacturer evaluation documented in the extracts article supersedes earlier blanket dual-use statements.

Are flower preparations inherently superior because of the entourage effect?

A more complete claimed plant profile is not direct evidence of a superior therapeutic effect. That would require specific products to be studied under appropriate comparative conditions. The mere presence of multiple compounds is not sufficient.

Nor is a concentrate with added terpenes clinically superior for that reason alone. A laboratory finding on a particular combination cannot straightforwardly be transferred to a differently composed mixture.

The terpene evidence matrix identifies which questions have been investigated in humans and where only preclinical results exist. It is the appropriate basis for evaluating such claims.

What does a higher concentration mean?

It means, in the first instance, more of a particular constituent per defined product quantity. This must be substantiated by an appropriate analysis. The quantity actually delivered and absorbed is not thereby determined.

A small visible amount cannot therefore be treated as a known low dose. Conversely, a larger herb load does not allow a higher THC quantity to be inferred without a stated concentration. Mass and concentration must be cited separately.

The earlier fixed concentration ranges for each texture, and their assignment to a particular expected effect, have been removed. They were incompatible with a batch-specific scientific assessment.

Can temperature ranges be compared directly?

A device set-point, a measured surface temperature, and the temperature within the plant material are three different quantities. Accordingly, a temperature figure from a concentrate system cannot be placed alongside a dry-herb vaporizer setting without explanation.

An emissions study on dabbing investigates a specific setup. It is not universal evidence for all concentrates, nor a directly transferable comparison with flower. The methodology description on thermal decomposition sets out the conditions.

For physical reference data, the following continues to apply: pressure and substance identity must be stated. A boiling point is not an efficacy or safety threshold.

How can a cost comparison be calculated honestly?

Begin by comparing known upfront and ongoing costs: the device, intended consumable parts, cleaning, and available spare parts. A difference in product mass alone is not a fair comparison of equivalent effect.

If chemical delivery is to be included, it requires appropriate measurement data. An assumed loss of active compound can substantially alter the calculation and should not remain hidden as an assumed value. The same applies to blanket shelf-life assumptions or a presupposed development of tolerance.

A transparent comparison therefore labels its assumptions and separates observed handling from medical or analytical claims.

What do reviews show about high THC potency?

Petrilli and colleagues included 20 observational studies. Higher potency was consistently associated with greater psychotic outcomes and cannabis use disorder compared with lower potency. Findings on depression and anxiety were less consistent. Definitions of ‘high-potency’ and patterns of use differed between studies. Petrilli et al. (2022)

A later systematic review encompassed 42 papers. Evidence was particularly consistent for problematic cannabis use, whilst other outcome domains were less uniform. The overall certainty of the evidence was rated as very low. This rating must appear directly alongside the risk signals, not only at the end of an article. Lake et al. (2025)

The reviews do not identify a fixed threshold below which all products would be safe. Nor do they demonstrate that product form alone, independent of dose, frequency, and user characteristics, causes a particular effect.

What questions remain open for aerosol chemistry?

Composition, thermal load, and device must be examined together. The library selected here does not contain a comprehensive toxicological ranking of all concentrate forms or cartridges. A dry-herb vaporizer laboratory finding must not fill this gap. Likewise, ‘manufactured without solvents’ is not a complete statement about the exposure generated during heating.

Frequently Asked Questions

Is rosin inherently suitable for use in a dry-herb vaporizer?

Only a matching device and material approval can answer that. The manufacturing method alone is not sufficient.

Are concentrates automatically lower in harmful substances?

No. Composition, residues and emissions must be tested for the specific product and system.

Are flowers inherently more versatile therapeutically?

Such an advantage must be demonstrated clinically. A full-spectrum claim alone is not proof of efficacy.

Is the same temperature comparable across both systems?

Only when it is clear which temperature is meant, at which location, and under which conditions.

Source status and changes

Revised on 10 September 2026. Studies and manufacturer statements are clearly separated in the linked specialist sections. Removed were blanket full-spectrum, purity and dosing claims, general texture percentages and unsubstantiated device approvals.

Petrilli K et al. (2022)

Study

Systematic review of observational studies

Sample

4.171 publications screened; 20 studies with approximately 119.581 participants in total.

Comparison and measurement

MEDLINE, Embase, PsycINFO to 14.01.2021; PROSPERO; high- vs low-potency cannabis, outcomes psychosis, anxiety, depression, CUD.

Randomisation and blinding

No.

Result

Higher potency was consistently associated with greater risk of psychosis and CUD; findings on depression and anxiety were mixed.

Strengths

Explicit potency question; established databases; PROSPERO; multiple outcomes.

Limitations and potential bias

Observational studies; definition of ‘high-potency’ differs across studies; potency correlates with use behaviour and product form.

Petrilli K, Ofori S, Hines L, Taylor G, Adams S, Freeman TP. 2022. Association of cannabis potency with mental ill health and addiction: a systematic review. The lancet. Psychiatry. DOI: 10.1016/S2215-0366(22)00161-4 · PMID 35901795

Petrilli K, Ofori S, Hines L, Taylor G, Adams S, Freeman TP. 2022. Association of cannabis potency with mental ill health and addiction: a systematic review. The lancet. Psychiatry. DOI: 10.1016/S2215-0366(22)00161-4 · PMID 35901795

Lake S et al. (2025)

Study

Systematic review of observational and experimental studies

Sample

4.545 records screened, 42 studies included.

Comparison and measurement

Five biomedical databases; predefined THC potency classes (1–9%, 10–19%, 20–30%, ~30–50%, concentrates ≥60%); two independent reviewers; GRADE.

Randomisation and blinding

Mixed designs; some experimental, many cross-sectional or observational.

Result

Evidence particularly for greater problematic cannabis use at higher potency; other health domains less consistent. Overall certainty of evidence: ‘very low’.

Strengths

Very current; absolute potency classes; independent screening and quality assessment; GRADE.

Limitations and potential bias

Predominantly cross-sectional; large research gaps regarding cardiorespiratory, cancer, and long-term outcomes.

Lake S, Murray CH, Henry B, Strong L, White K, Kilmer B, Cooper ZD. 2025. High-Potency Cannabis Use and Health: A Systematic Review of Observational and Experimental Studies. The American journal of psychiatry. DOI: 10.1176/appi.ajp.20240269 · PMID 40134269 · PMC12549548

Lake S, Murray CH, Henry B, Strong L, White K, Kilmer B, Cooper ZD. 2025. High-Potency Cannabis Use and Health: A Systematic Review of Observational and Experimental Studies. The American journal of psychiatry. DOI: 10.1176/appi.ajp.20240269 · PMID 40134269 · PMC12549548